Hello everyone! Today we bring excellent news for the medical and patient community. The U.S. Food and Drug Administration (FDA) has taken an important step in the treatment of certain types of blood cancer.
On December 3, 2025, the FDA granted traditional approval to pirtobrutinib (commercially known as Jaypirca), developed by Eli Lilly and Company.
Who is this treatment for?
This medication is specifically indicated for adults who suffer from:
-
Chronic Lymphocytic Leukemia (CLL) or
-
Small Lymphocytic Lymphoma (SLL)
The approval focuses on patients suffering from relapsed or refractory disease (meaning it has returned or has not responded to treatment) and who have already been previously treated with a covalent BTK inhibitor.
Context note: Jaypirca had already received accelerated approval in 2023 for patients with more advanced therapy lines, but this new decision solidifies its status based on more robust clinical data.
Why was it approved? The Evidence
The FDA's decision is based on the results of the BRUIN-CLL-321 clinical trial. This study compared the use of pirtobrutinib against other standard therapies (such as idelalisib with rituximab or bendamustine with rituximab).
The results were clear:
-
Longer progression-free time: Patients who took pirtobrutinib had a median progression-free survival of 11.2 months, compared to 8.7 months in the control group.
-
Risk reduction: The study showed that the medication significantly reduced the risk of disease progression compared to the other options studied.
Key Data on Safety and Dosage
As with any potent medication, it is vital to know both its use and its risks:
-
Recommended dose: 200 mg orally, once daily, until disease progression or unacceptable toxicity occurs.
-
Precautions: The prescribing information includes warnings about infections, bleeding, cytopenias (low blood cell count), cardiac arrhythmias, and hepatotoxicity, among others.
Why is this important?
For patients with CLL or SLL who have exhausted standard BTK inhibitor options, effective alternatives can be limited. This traditional approval confirms that pirtobrutinib is not just a promising option, but a validated tool for extending disease control time in a difficult-to-treat population.
Information from: FDA
What's next?
If you want to train your group of KOLs in impact communication and storytelling, we can schedule an exploratory call to understand your needs and make you a training proposal. Leaderlix trains the leaders of the most emblematic companies in their industries in high-impact presentations.
{% module_block module "widget_ec52af82-74c5-42a7-b877-e2f9ae2e26e1" %}{% module_attribute "child_css" is_json="true" %}{% raw %}null{% endraw %}{% end_module_attribute %}{% module_attribute "css" is_json="true" %}{% raw %}null{% endraw %}{% end_module_attribute %}{% module_attribute "label" is_json="true" %}{% raw %}null{% endraw %}{% end_module_attribute %}{% module_attribute "meeting" is_json="true" %}{% raw %}"https://leaderlix.com/meetings/gerardo-betancourt/tu-llamada-exploratoria-fda"{% endraw %}{% end_module_attribute %}{% module_attribute "module_id" is_json="true" %}{% raw %}33947244299{% endraw %}{% end_module_attribute %}{% module_attribute "schema_version" is_json="true" %}{% raw %}2{% endraw %}{% end_module_attribute %}{% module_attribute "tag" is_json="true" %}{% raw %}"module"{% endraw %}{% end_module_attribute %}{% end_module_block %}